Related Articles
Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma
Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy
Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer
Use of clinicopathological factors to predict prognosis of fertility‑sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy